title: Changes in progesterone-induced-blocking-factor expression rates following mifepristone administration in termination of pregnancy at 5 to 8 weeks.
abstract: OBJECTIVE
  To study changes in the expression rate of PIBF by peripheral lymphocytes in healthy pregnant women after administration of mifepristone for non-surgical termination of pregnancy at 5-8 wks of gestation.
  
  
  METHODS
  Patients requesting early social termination of pregnancy, in a 3-month period, were included. A first venous blood sample was taken before oral administration of 600 mg of mifepristone (day 0). A second venous blood sample was taken 2 days later. PIBF on lymphocytes was determined by immunocytochemistry using a PIBF-specific polyclonal antibody.
  
  
  RESULTS
  Termination of pregnancy was successful and complete in all cases. In 17 out of 21 patients, the percentage of PIBF positive lymphocytes decreased after anti-progesterone administration. The percentage of PIBF-expressing lymphocytes significantly decreased from 52.8%+/-21.6% (day 0) to 39.8%+/-18.2% by day 2 (p=0.001).
  
  
  CONCLUSIONS
  These data suggest a strong relationship between early termination of pregnancy induced with mifepristone and disturbances of progesterone-mediated immunosuppression.
authors.affiliation: Department of Obstetrics and Gynecology, Poissy-Saint Germain Hospital, Versailles-St Quentin University, France.
authors.forename: Laurent J
authors.initials: LJ
authors.lastname: Salomon
authors.forename: Patrick
authors.initials: P
authors.lastname: Rozenberg
authors.forename: Julia
authors.initials: J
authors.lastname: Szekeres-Bartho
authors.forename: Lydia
authors.initials: L
authors.lastname: Malagrida
authors.forename: Yves
authors.initials: Y
authors.lastname: Giudicelli
authors.forename: Yves
authors.initials: Y
authors.lastname: Ville
mesh_terms: D000021:Abortifacient Agents, Steroidal / Q000008:administration & dosage / Q000494:pharmacology*; D000028:Abortion, Induced; D000284:Administration, Oral; D000328:Adult; D005260:Female; D006801:Humans; D008214:Lymphocytes / Q000187:drug effects*; D015735:Mifepristone / Q000008:administration & dosage / Q000494:pharmacology*; D011247:Pregnancy; D011257:Pregnancy Proteins / Q000187:drug effects*; D011261:Pregnancy Trimester, First; D013491:Suppressor Factors, Immunologic / Q000008:administration & dosage*
chemical_list: D000021:Abortifacient Agents, Steroidal; C110058:PIBF1 protein, human; D011257:Pregnancy Proteins; D013491:Suppressor Factors, Immunologic; D015735:Mifepristone